vs
Drilling Tools International Corp（DTI）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
Drilling Tools International Corp的季度营收约是REGENXBIO Inc.的1.3倍（$38.5M vs $30.3M），Drilling Tools International Corp净利率更高（3.2% vs -221.3%，领先224.5%），REGENXBIO Inc.同比增速更快（43.0% vs -3.4%），Drilling Tools International Corp自由现金流更多（$1.3M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 2.1%）
Drilling Tools International Corp是一家领先的钻探工具供应商，面向油气勘探开采领域提供专用钻探设备、租赁服务及配套技术支持，主要服务北美及全球其他核心能源市场的陆上、海上钻井运营商与油田服务企业，助力提升钻探作业的效率与安全性。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
DTI vs RGNX — 直观对比
营收规模更大
DTI
是对方的1.3倍
$30.3M
营收增速更快
RGNX
高出46.4%
-3.4%
净利率更高
DTI
高出224.5%
-221.3%
自由现金流更多
DTI
多$54.1M
$-52.8M
两年增速更快
RGNX
近两年复合增速
2.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $38.5M | $30.3M |
| 净利润 | $1.2M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 2.9% | -190.0% |
| 净利率 | 3.2% | -221.3% |
| 营收同比 | -3.4% | 43.0% |
| 净利润同比 | 190.6% | -31.2% |
| 每股收益（稀释后） | $0.04 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DTIRGNX
| Q4 25 | $38.5M | $30.3M | ||
| Q3 25 | $38.8M | $29.7M | ||
| Q2 25 | $39.4M | $21.4M | ||
| Q1 25 | $42.9M | $89.0M | ||
| Q4 24 | $39.8M | $21.2M | ||
| Q3 24 | $40.1M | $24.2M | ||
| Q2 24 | $37.5M | $22.3M | ||
| Q1 24 | $37.0M | $15.6M |
净利润DTIRGNX
| Q4 25 | $1.2M | $-67.1M | ||
| Q3 25 | $-903.0K | $-61.9M | ||
| Q2 25 | $-2.4M | $-70.9M | ||
| Q1 25 | $-1.7M | $6.1M | ||
| Q4 24 | $-1.3M | $-51.2M | ||
| Q3 24 | $867.0K | $-59.6M | ||
| Q2 24 | $365.0K | $-53.0M | ||
| Q1 24 | $3.1M | $-63.3M |
毛利率DTIRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率DTIRGNX
| Q4 25 | 2.9% | -190.0% | ||
| Q3 25 | -1.2% | -176.3% | ||
| Q2 25 | -4.2% | -296.3% | ||
| Q1 25 | 7.7% | 13.6% | ||
| Q4 24 | 4.5% | -242.1% | ||
| Q3 24 | 10.6% | -256.6% | ||
| Q2 24 | 6.0% | -251.3% | ||
| Q1 24 | 13.9% | -408.8% |
净利率DTIRGNX
| Q4 25 | 3.2% | -221.3% | ||
| Q3 25 | -2.3% | -208.3% | ||
| Q2 25 | -6.1% | -331.8% | ||
| Q1 25 | -3.9% | 6.8% | ||
| Q4 24 | -3.4% | -241.3% | ||
| Q3 24 | 2.2% | -246.3% | ||
| Q2 24 | 1.0% | -237.7% | ||
| Q1 24 | 8.5% | -405.4% |
每股收益（稀释后）DTIRGNX
| Q4 25 | $0.04 | $-1.30 | ||
| Q3 25 | $-0.03 | $-1.20 | ||
| Q2 25 | $-0.07 | $-1.38 | ||
| Q1 25 | $-0.05 | $0.12 | ||
| Q4 24 | $-0.06 | $-0.99 | ||
| Q3 24 | $0.03 | $-1.17 | ||
| Q2 24 | $0.01 | $-1.05 | ||
| Q1 24 | $0.11 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.6M | $230.1M |
| 总债务越低越好 | $45.8M | — |
| 股东权益账面价值 | $122.9M | $102.7M |
| 总资产 | $222.2M | $453.0M |
| 负债/权益比越低杠杆越低 | 0.37× | — |
8季度趋势，按日历期对齐
现金及短期投资DTIRGNX
| Q4 25 | $3.6M | $230.1M | ||
| Q3 25 | $4.4M | $274.2M | ||
| Q2 25 | $1.1M | $323.3M | ||
| Q1 25 | $2.8M | $267.9M | ||
| Q4 24 | $6.2M | $234.7M | ||
| Q3 24 | $12.0M | $255.5M | ||
| Q2 24 | $6.8M | $290.4M | ||
| Q1 24 | $14.1M | $338.7M |
总债务DTIRGNX
| Q4 25 | $45.8M | — | ||
| Q3 25 | $51.3M | — | ||
| Q2 25 | $56.9M | — | ||
| Q1 25 | $54.9M | — | ||
| Q4 24 | $53.8M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益DTIRGNX
| Q4 25 | $122.9M | $102.7M | ||
| Q3 25 | $121.1M | $161.5M | ||
| Q2 25 | $122.5M | $213.7M | ||
| Q1 25 | $122.7M | $274.2M | ||
| Q4 24 | $120.0M | $259.7M | ||
| Q3 24 | $-123.2M | $301.4M | ||
| Q2 24 | $92.8M | $348.3M | ||
| Q1 24 | $91.5M | $390.7M |
总资产DTIRGNX
| Q4 25 | $222.2M | $453.0M | ||
| Q3 25 | $227.4M | $525.2M | ||
| Q2 25 | $230.3M | $581.0M | ||
| Q1 25 | $233.2M | $490.9M | ||
| Q4 24 | $222.4M | $466.0M | ||
| Q3 24 | $218.8M | $519.1M | ||
| Q2 24 | $166.9M | $569.4M | ||
| Q1 24 | $167.0M | $629.2M |
负债/权益比DTIRGNX
| Q4 25 | 0.37× | — | ||
| Q3 25 | 0.42× | — | ||
| Q2 25 | 0.46× | — | ||
| Q1 25 | 0.45× | — | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $5.3M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $1.3M | $-52.8M |
| 自由现金流率自由现金流/营收 | 3.4% | -174.0% |
| 资本支出强度资本支出/营收 | 10.4% | 1.7% |
| 现金转化率经营现金流/净利润 | 4.38× | — |
| 过去12个月自由现金流最近4个季度 | $-224.0K | $-126.4M |
8季度趋势，按日历期对齐
经营现金流DTIRGNX
| Q4 25 | $5.3M | $-52.3M | ||
| Q3 25 | $10.0M | $-56.0M | ||
| Q2 25 | $2.2M | $-49.3M | ||
| Q1 25 | $2.4M | $33.6M | ||
| Q4 24 | $-3.7M | $-31.6M | ||
| Q3 24 | $5.3M | $-40.5M | ||
| Q2 24 | $1.1M | $-45.5M | ||
| Q1 24 | $3.3M | $-55.5M |
自由现金流DTIRGNX
| Q4 25 | $1.3M | $-52.8M | ||
| Q3 25 | $6.4M | $-56.5M | ||
| Q2 25 | $-5.4M | $-49.7M | ||
| Q1 25 | $-2.6M | $32.6M | ||
| Q4 24 | $-6.9M | $-32.7M | ||
| Q3 24 | $2.0M | $-40.9M | ||
| Q2 24 | $-9.0M | $-46.0M | ||
| Q1 24 | $-2.9M | $-56.0M |
自由现金流率DTIRGNX
| Q4 25 | 3.4% | -174.0% | ||
| Q3 25 | 16.5% | -189.9% | ||
| Q2 25 | -13.6% | -232.8% | ||
| Q1 25 | -6.1% | 36.6% | ||
| Q4 24 | -17.3% | -154.2% | ||
| Q3 24 | 4.9% | -168.9% | ||
| Q2 24 | -24.0% | -206.2% | ||
| Q1 24 | -7.9% | -358.5% |
资本支出强度DTIRGNX
| Q4 25 | 10.4% | 1.7% | ||
| Q3 25 | 9.1% | 1.7% | ||
| Q2 25 | 19.2% | 1.8% | ||
| Q1 25 | 11.8% | 1.2% | ||
| Q4 24 | 8.1% | 5.1% | ||
| Q3 24 | 8.4% | 1.3% | ||
| Q2 24 | 26.9% | 2.1% | ||
| Q1 24 | 16.8% | 3.6% |
现金转化率DTIRGNX
| Q4 25 | 4.38× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | 6.15× | — | ||
| Q2 24 | 2.96× | — | ||
| Q1 24 | 1.06× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DTI
| Tool Rental | $30.4M | 79% |
| Products | $8.1M | 21% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
